seekingalpha.com Earnings
Altimmune outlines PERFORMA Phase III MASH 52-week data readout expected in 2029 while advancing AUD Phase III planning
Earnings Call Insights: Altimmune (ALT) Q2 2026 MANAGEMENT VIEW * "2026 is proving to be a year of significant progress as Altimmune evolves into a late-stage company dedicated to serious liver diseases," said Chairman, CEO & President Jerome Durso, adding, "Last week we announced the initiation of the PERFORMA Phase III trial as we began enrolling patients in …